Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC
/ Cherrishe Brown-Bickerstaff / Jan Andreasen
Efficacy of 1L Treatment Does Not Predict Efficacy of 2L Cabozantinib for Patients with mRCC
/ Martin Zarba / Jan Andreasen
Danish Study Reveals Doubling of Kidney Cancer Cases and a Growing Gender Gap
/ Johanne Ahrenfeldt / Jan Andreasen